Nanoparticles targeted to cancer cells by antibodies cannot achieve enough specificity to kill drug-resistant cancer cells while sparing normal cells, but can achieve enough specificity to produce nanobubbles only in cancer cells, so the drug only enters cancer cells.
Drug-resistant cancer cells cannot resist plasmonic nanobubbles
